The Prognostic Value of Serum Biomarkers for Survival of Children with Osteosarcoma of the Extremities

Curr Oncol. 2023 Jul 24;30(7):7043-7054. doi: 10.3390/curroncol30070511.

Abstract

Background: Osteosarcoma is a highly aggressive malignant bone tumor that affects mainly adolescents and young adults. We analyzed serum biomarkers for their prognostic significance in children with osteosarcoma.

Methods: In this retrospective study, we investigated the prognostic factors in 210 children who were treated for appendicular osteosarcoma, including patient age and sex, tumor site and size (≥8 cm or <8 cm), presence of metastasis, chemotherapy-induced tumor necrosis, serum levels of alkaline phosphatase (AP), C-reactive protein, serum hemoglobin, lactate dehydrogenase, erythrocyte sedimentation rate (ESR), leukocyte counts, platelet count, and neutrophil-lymphocyte ratio.

Results: A multivariate Cox regression model showed that high level of AP [HR of 1.73; 95% CI, 1.02 to 2.94], poor chemotherapy-induced tumor necrosis [HR of 2.40; 95% CI, 1.41 to 4.08] and presence of metastases at presentation [HR of 3.71; 95% CI, 2.19 to 6.29] were associated with poor prognosis at 5 years (p < 0.05). Inadequate surgical margins [HR 11.28; 95% CI, 1.37 to 92.79] and high levels of ESR [HR 3.58; 95% CI, 1.29 to 9.98] showed a greater risk of local recurrence at 5 years follow-up (p < 0.05).

Conclusions: AP and ESR can identify osteosarcoma-diagnosed children with a greater risk of death and local recurrence, respectively.

Trial registration: ClinicalTrials.gov NCT05093101.

Keywords: C-reactive protein; alkaline phosphatase; chemotherapy-induced tumor necrosis; children; erythrocyte sedimentation rate; local recurrence; osteosarcoma; prognosis; serological biomarker; survival.

MeSH terms

  • Adolescent
  • Antineoplastic Agents*
  • Biomarkers
  • Bone Neoplasms* / surgery
  • Child
  • Extremities / pathology
  • Humans
  • Necrosis
  • Osteosarcoma* / pathology
  • Osteosarcoma* / surgery
  • Prognosis
  • Retrospective Studies
  • Young Adult

Substances

  • Biomarkers
  • Antineoplastic Agents

Associated data

  • ClinicalTrials.gov/NCT05093101

Grants and funding

This research received no external funding.